In an incredibly strong year for all the big-cap biotech stocks, Hugin steered Celgene to the top of the heap. The multiple myeloma drug Revlimid remains Celgene's most important profit driver, but the company did well to diversify in 2013. Pomalyst, Abraxane and apremilast were all big winners for the company this year. Under Hugin's direction, Celgene also signed a large number of drug development partnerships for early-stage compounds which makes the company a player in emerging technologies.
Congratulations, Bob, for a fantastic year and well-deserved recognition as the Best Biotech CEO of 2013.
Hugin won with 41% of 1,078 votes cast. For his victory, Hugin takes home the Swanson Trophy, named in honor of Robert Swanson, Genentech's founding CEO.The runner-up this year was John Higgins of Ligand Pharmaceuticals (LGND - Get Report) with 25% of votes cast. Francois Nader of NPS Pharmaceuticals (NPSP - Get Report) finished in third place with 11% of the vote, followed closely by Lamberto Andreotti of Bristol-Myers Squibb (BMY) and Onyx Pharmaceuticals' (now a part of Amgen (AMGN - Get Report)) Tony Coles. Congratulation to all of this year's Best Biotech CEO nominees, and thanks to everyone who participated in the voting process. -- Reported by Adam Feuerstein in Boston. Follow Adam Feuerstein on Twitter.
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts